Morgan Stanley Call 170 BGNE 20.0.../ DE000ME9RY46 /
| 2024-06-04 4:51:56 PM | Chg.+0.13 | Bid5:07:11 PM | Ask5:07:11 PM | Underlying | Strike price | Expiration date | Option type |
|---|---|---|---|---|---|---|---|
| 1.27EUR | +11.40% | 1.27 Bid Size: 7,500 |
1.53 Ask Size: 7,500 |
BeiGene Ltd | 170.00 USD | 2024-09-20 | Call |
GlobeNewswire
05-28
BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS™ First in Human Study
GlobeNewswire
05-14
SELLAS Life Sciences Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
05-02
Zymeworks Provides Corporate Update and Reports First Quarter 2024 Financial Results
GlobeNewswire
05-02
SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business...
GlobeNewswire
04-11
Zymeworks To Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
GlobeNewswire
03-28
SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update
GlobeNewswire
03-28
Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlight...
GlobeNewswire
03-05
Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate and Multispecific Platforms at the ...
GlobeNewswire
02-27
MAIA Biotechnology Appoints Leading Immuno-Oncology Scientist Dr. Remus Vezan as Scientific Advisor
GlobeNewswire
02-27
SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights ...
GlobeNewswire
02-08
Zymeworks Announces Appointment of Dr. Alessandra Cesano to its Board of Directors
